Core Insights - UroGen Pharma Ltd. supports the Bladder Cancer Advocacy Network's report highlighting the chronic and recurrent nature of bladder cancer, emphasizing the need for improved patient care and understanding [1][4] Patient Survey Findings - The survey involved over 1,100 bladder cancer patients in the U.S., revealing that nearly 80% fear recurrence, with over 90% of patients under 50 sharing this concern [2][7] - Among female respondents, 86% reported fear of recurrence, while 87% of patients who retained their bladder expressed ongoing concern [2] - The report indicates a significant procedural burden, with many patients undergoing five or more cystoscopies, and some experiencing over 15 procedures throughout their treatment [2][7] Clinical Implications - The findings underscore that bladder cancer is often a chronic condition characterized by recurrence and repeated procedures, necessitating treatment discussions that prioritize long-term quality of life and emotional well-being [3] - The survey included diverse clinical experiences, with 47% of respondents initially diagnosed with non-muscle invasive bladder cancer (NMIBC), 23% with carcinoma in situ (CIS), and 22% with muscle-invasive disease (MIBC) [3] Company Overview - UroGen Pharma is focused on developing innovative therapies for urothelial and specialty cancers, utilizing proprietary sustained-release hydrogel technology to enhance treatment efficacy [6] - The company has two approved products aimed at treating low-grade upper tract urothelial cancer and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, both designed for non-surgical tumor ablation [6]

Core Viewpoint - Investing is viewed as a learning process where failures serve as tuition and successes contribute to lessons learned [1] Group 1 - The author has approximately 5 years of focused research on various stocks, with a primary emphasis on healthcare stocks [1] - The author appreciates feedback from readers, especially those sharing relevant anecdotes and experiences [1] Group 2 - The author has a beneficial long position in URGN shares, indicating a personal investment interest [2] - The article expresses the author's own opinions and is not influenced by compensation from any company mentioned [2]

UroGen Pharma FY Conference Summary Company Overview - **Company**: UroGen Pharma (NasdaqGM:URGN) - **Industry**: Biotechnology, specifically focused on bladder cancer treatments Key Highlights - **Transformational Year**: UroGen is experiencing a pivotal year with the approval of JELMYTO for bladder cancer, marking a significant milestone since the company's inception [10][11] - **Financial Position**: The company has successfully completed debt refinancing, enhancing its financial stability and flexibility for future growth [60][61] - **Product Launch**: JELMYTO's launch is unique as it involves a procedure rather than a traditional pill or infusion, impacting the treatment timeline for patients [16][17] Financial Performance - **Q4 Results**: UroGen reported Q4 revenues of approximately $14 million, with $4.5 million generated in October alone, indicating strong initial uptake [19] - **Growth Expectations**: The company anticipates accelerated growth following the introduction of a permanent J-code, which is crucial for reimbursement confidence among physicians [17][20] Market Dynamics - **Patient Enrollment**: About 80% to 90% of patients are processed through a hub that manages patient enrollment forms, which are critical for tracking demand [23][25] - **Conversion Rates**: The conversion rate from patient enrollment forms to actual treatments is currently around 70%-80%, with efforts to reduce the time from enrollment to treatment [31][25] Competitive Landscape - **Unique Positioning**: UroGen is the only company offering a treatment for low-grade non-muscle invasive bladder cancer, differentiating itself from competitors [18] - **Market Potential**: The bladder cancer market is estimated to be a $5 billion opportunity, with UroGen aiming to capture a significant share through its innovative treatments [35][36] Pipeline Developments - **UGN-103**: This next-generation formulation is expected to have patent protection until 2042, with clinical data anticipated mid-year [66] - **UGN-501**: An oncolytic virus with potential applications beyond bladder cancer, currently in early development stages [70][71] Strategic Vision - **Long-term Growth**: UroGen aims to build a sustainable growth company by leveraging its unique product offerings and expanding its market presence [10][12] - **Focus on Education**: The company is committed to educating physicians on the benefits of its treatments to drive adoption and increase patient access [35][46] Undervalued Aspects - **Market Valuation**: The CEO highlighted that the market valuation does not fully reflect the potential of ZUSDURI, which could represent a $1.2 billion opportunity if the company captures 20% of the patient population [76] Conclusion - UroGen Pharma is positioned for significant growth in the bladder cancer treatment market, with a strong financial foundation, innovative products, and a strategic focus on education and market penetration. The upcoming quarters will be critical in determining the trajectory of its growth and market acceptance.

Core Viewpoint - UroGen Pharma Ltd. is focused on developing innovative solutions for urological and uro-oncological diseases, with key products showing growth and strategic initiatives aimed at enhancing market presence and financial stability [1][5]. Financial Performance - UroGen Pharma reported a quarterly loss of $0.54 per share for Q4 2025, which is better than the Zacks Consensus Estimate of a $0.66 loss and an improvement from the $0.80 loss in the same quarter last year, indicating an 18.18% positive earnings surprise [3][6]. - The company achieved $37.84 million in revenue for Q4 2025, surpassing the Zacks Consensus Estimate by 6.42% and showing significant growth from $24.57 million in the same quarter the previous year [4][6]. Stock Performance - Oppenheimer reiterated its "Outperform" rating for UroGen Pharma, maintaining a stock price of $19.93 at the time of the report, despite a recent decrease of 8.06% [2]. - The stock has fluctuated between $18.18 and $21.69, with a market capitalization of approximately $933.8 million [2]. Strategic Initiatives - UroGen launched ZUSDURI™, achieving net sales of $15.8 million in 2025, and the introduction of a permanent J Code effective January 1, 2026, is expected to improve reimbursement processes and patient access [5][6]. - The company has refinanced its existing term loan with Pharmakon Advisors, securing additional non-dilutive capital under more favorable terms [5].

Core Insights - UroGen Pharma is experiencing early commercial momentum for its newly launched product Zusduri, particularly following the implementation of a permanent J-code that has improved patient access and engagement from urologists [3][6][10] Financial Performance - In 2025, UroGen reported total revenue of $109.8 million, an increase from $90.4 million in 2024, driven by the launch of Zusduri and growth in Jelmyto sales [5][16] - The company recorded a net loss of $153.5 million in 2025, compared to a net loss of $126.9 million in 2024, with cash and marketable securities totaling $120.5 million as of December 31, 2025 [5][18] Product Launch and Market Dynamics - Zusduri generated $15.8 million in revenue for 2025, with $1.8 million in net product revenue in Q3 and $14.0 million in Q4 [2][6] - By the end of 2025, there were 838 activated sites of care for Zusduri, with over 95% of covered lives having open access to the treatment [7][10] Clinical Outcomes and Feedback - The ENVISION trial supporting Zusduri's approval showed an approximately 80% complete response rate at three months, with a high probability of remaining event-free at 12 and 24 months [8] - Anecdotal feedback from physicians indicates that Zusduri integrates smoothly into practice, offering a non-surgical outpatient option that is valued by patients [9] Future Developments - UroGen plans to submit an NDA for UGN-103 in the second half of 2026, with potential approval in 2027, and aims to transition to UGN-103 quickly after obtaining a permanent J-code [11][13] - The company is also evaluating UGN-104 and UGN-501, with ongoing clinical trials and plans for future studies [14][15] Operational Strategy - The company is investing heavily in the commercialization of Zusduri, with a focus on building infrastructure that will support future products like UGN-103 [22] - UroGen's refinancing efforts have reduced the cost of capital and extended repayment timelines, providing added flexibility for future growth [19][22]

Financial Data and Key Metrics Changes - Total revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of ZUSDURI and increased sales of JELMYTO [19][20] - The net loss for the year was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - ZUSDURI generated $15.8 million in revenue for 2025, reflecting early launch dynamics [5][14] - JELMYTO generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [7][17] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care with 102 unique prescribers and 32 repeat prescribers for ZUSDURI [15] - Over 95% of covered lives had open access to ZUSDURI by year-end 2025 [15] Company Strategy and Development Direction - The company’s top priority is the commercial launch of ZUSDURI, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5][7] - The company is advancing its pipeline with UGN-103 and UGN-104, with plans to submit an NDA for UGN-103 in the second half of 2026 [8][12] - A refinancing of the debt facility with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility [8][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early trajectory of ZUSDURI's launch and noted that the permanent J-code has facilitated more predictable patient access [5][6] - The company anticipates that the conversion timeline from patient enrollment forms to dosing will narrow as sites gain familiarity with the product [16] - Management is optimistic about the potential for ZUSDURI and its pipeline products to create long-term value for patients and shareholders [9][23] Other Important Information - The company expects JELMYTO net product revenues for 2026 to be in the range of $97 million to $101 million, reflecting a year-over-year growth rate of approximately 3% to 7% [23] - Full-year 2026 operating expenses are expected to be in the range of $240 million to $250 million, driven by increased sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for ZUSDURI - Management indicated that they would consider providing formal guidance for ZUSDURI after gaining visibility into steady-state demand, approximately two quarters post the permanent J-code [29] - The number of patient enrollment forms has increased since the permanent J-code became effective, with new and repeat prescribers contributing to this growth [31][32] Question: Trends in repeat prescribers and their likelihood of becoming repeat prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement and repeat prescribing [39] Question: Timing for UGN-103 market introduction and its commercial positioning - UGN-103 is expected to be introduced after obtaining a permanent J-code, with a potential launch in early 2028 [41] Question: Current use of ZUSDURI among patients and expected shifts in use patterns - ZUSDURI is being used primarily for patients who recur early, have frequent recurrences, or are unfit for surgery, with expectations for increased utilization as community practices gain experience [48][49] Question: Opportunities for ZUSDURI in the adjuvant setting - There is enthusiasm for expanding UGN-103 into the adjuvant setting for new diagnoses, with ongoing discussions about potential combinations with other agents [60][61]

Financial Data and Key Metrics Changes - Total revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of Zusduri and increased sales of Jelmyto [19] - Net loss for 2025 was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - Zusduri generated $15.8 million in revenue for 2025, reflecting early launch dynamics [5] - Jelmyto generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [7][17] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care for Zusduri, with 102 unique prescribers and 32 repeat prescribers [15] - Over 95% of covered lives had open access to Zusduri by year-end 2025, facilitating broader adoption [15] Company Strategy and Development Direction - The primary focus is on the commercial launch of Zusduri, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5][7] - The company is advancing its pipeline, including UGN-103 and UGN-104, with plans for NDA submissions and potential FDA approvals in 2026 and 2027 [8][12] - A refinancing agreement with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility, supporting ongoing initiatives [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early trajectory of Zusduri's launch, with key indicators showing acceleration in prescriber engagement and patient access following the implementation of a permanent J-code [5][15] - The company anticipates narrowing conversion timelines from patient enrollment to dosing as sites gain familiarity with the product [16] Other Important Information - The company is not providing formal sales guidance for Zusduri in 2026 due to its early launch stage but expects to offer guidance after gaining visibility into steady-state demand [29] - Operating expenses for 2026 are expected to be in the range of $240 million to $250 million, driven by sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for Zusduri - Management indicated that they expect to provide formal guidance for Zusduri at least two quarters post the permanent J-code implementation [29] - There has been a noticeable increase in key indicators, including patient enrollment forms, since the J-code became effective [31][32] Question: Trends in repeat prescribers and feedback from new prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement [38] - New prescribers are waiting for clean claim submissions and reimbursement confidence before becoming repeat prescribers [38] Question: Timing for UGN-103 market introduction and its relationship with Zusduri - UGN-103 is expected to be introduced after obtaining a permanent J-code, likely in early 2028 [40][41] Question: Current use patterns for Zusduri among patients - Zusduri is primarily used for patients who recur early, have frequent recurrences, or are unfit for surgery, with enthusiasm from physicians regarding its efficacy [47] Question: Opportunities for Zusduri in the adjuvant setting - There is interest in exploring Zusduri in the adjuvant setting for high-risk disease, with ongoing protocol finalization for trials [59][60]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of Zusduri and increased sales of Jelmyto [18] - The net loss for 2025 was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - Zusduri generated $15.8 million in revenue for 2025, reflecting early launch dynamics [4] - Jelmyto generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [5][16] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care with 102 unique prescribers and 32 repeat prescribers for Zusduri [14] - Over 95% of covered lives had open access to Zusduri by year-end 2025 [14] Company Strategy and Development Direction - The primary focus is on the commercial launch of Zusduri, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5] - The company is advancing its pipeline, including UGN-103 and UGN-104, with plans for NDA submissions and potential FDA approvals in 2026 and 2027 [6][11] - A refinancing agreement with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility [7][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early adoption of Zusduri, with positive feedback from prescribers and patients regarding its ease of use and clinical effectiveness [9][10] - The company anticipates that the conversion timeline from patient enrollment forms to dosing will improve as sites gain familiarity with the product [15] Other Important Information - The company is not providing formal sales guidance for Zusduri in 2026 due to its early launch stage but expects Jelmyto net product revenues to be in the range of $97 million to $101 million [23] - Full-year 2026 operating expenses are expected to be between $240 million and $250 million, driven by sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for Zusduri - Management indicated that they could consider providing formal guidance for Zusduri at least two quarters post the permanent J-code [28] - There has been a noticeable increase in key indicators since the J-code became effective, including new and repeat prescribers [30][31] Question: Trends in repeat prescribers and feedback from non-repeat prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement [36] Question: Lifecycle management and market introduction of UGN-103 - UGN-103 is expected to be introduced after obtaining a permanent J-code, with a potential launch in early 2028 [38] Question: Current use of Zusduri among different patient types - Zusduri is being used primarily for patients who recur early, have frequent recurrences, or are unfit for surgery, with enthusiasm from physicians regarding its clinical data [45][46] Question: Community versus academic center adoption of Zusduri - The utilization mix has shifted towards community settings, with approximately 50% of usage now in community practices [53][54]

分组1 - Urogen Pharma reported a quarterly loss of $0.54 per share, better than the Zacks Consensus Estimate of a loss of $0.66, and improved from a loss of $0.8 per share a year ago, resulting in an earnings surprise of +18.18% [1] - The company posted revenues of $37.84 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 6.42%, and showing a significant increase from year-ago revenues of $24.57 million [2] - Urogen Pharma has surpassed consensus EPS estimates two times over the last four quarters, while it has topped consensus revenue estimates only once during the same period [2] 分组2 - The stock has underperformed the market, losing about 7.3% since the beginning of the year, compared to the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.58 on revenues of $42.73 million, and for the current fiscal year, it is -$1.13 on revenues of $250.54 million [7] - The Medical - Biomedical and Genetics industry, to which Urogen Pharma belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Market Opportunity - Zusduri has an estimated total addressable market opportunity of over $5.0 billion for recurrent low-grade intermediate risk NMIBC, with an annual treatable population of approximately 82,000 in the U.S.[511] Clinical Trial Results - The CR rate for Zusduri in the ENVISION trial was 79.6% at three months, with 60.8% of all enrolled patients in CR at 12 months[526] - Jelmyto achieved a CR rate of 58% in the Olympus trial, with a durability of response estimated at 81.8% at 12 months[518] - The ENVISION trial demonstrated a 72.2% DOR at 24 months for patients who achieved CR at three months[528] - In the Phase 3 ENVISION trial, 78% of patients achieved complete response (CR) at three months, with 79% of those maintaining CR at 12 months[531] - The Phase 3b study showed that 75% of patients achieved CR after home administration of Zusduri, with six out of eight patients completing all six instillations[530] - The median duration of response for patients achieving CR with Jelmyto was not reached, with a median follow-up of 28.1 months[519] - The median duration of response (DOR) for patients in the OPTIMA II trial was 24.2 months, with a median follow-up of 35.8 months[529] - The UTOPIA trial for UGN-103 enrolled 99 patients globally, with a three-month CR rate of 77.8%[536] Regulatory Approvals - The FDA approved Zusduri on June 12, 2025, for the treatment of adults with recurrent low-grade intermediate risk NMIBC[523] - The FDA approved Zusduri on June 12, 2025, based on data from 223 patients in the ENVISION trial[531] - Jelmyto's new product exclusivity expired on April 15, 2023, but Orphan Drug exclusivity extends until April 15, 2027[515] - Medicare has established a permanent J-code for Jelmyto effective January 1, 2021, and granted it a New Technology APC effective October 1, 2023[522] Financial Performance - The company recognized $109.8 million in revenue for the year ended December 31, 2025, compared to $90.4 million in 2024, reflecting a 21.5% increase[551] - Revenue for the year ended December 31, 2025, was $109.8 million, an increase of $19.4 million from $90.4 million in 2024, primarily driven by sales of Zusduri and increased sales of Jelmyto[574] - Net cash used in operating activities increased to $162.4 million for the year ended December 31, 2025, compared to $96.8 million in 2024, primarily due to higher operating expenses[600] - The net loss for the year ended December 31, 2025, was $153.5 million, compared to a net loss of $126.9 million in 2024, reflecting an increase of $26.6 million[573] Research and Development - Research and development expenses totaled $67.1 million in 2025, up from $57.1 million in 2024, indicating a 17.5% increase[555] - The company anticipates continued increases in research and development expenses as clinical programs progress and additional product candidates are developed[558] - Research and development expenses rose to $67.1 million in 2025 from $57.1 million in 2024, an increase of $10.0 million attributed to higher manufacturing costs for Zusduri and costs associated with clinical trials[576] Marketing and Sales - Selling and marketing expenses increased to $99.1 million in 2025 from $75.2 million in 2024, reflecting a rise of $23.9 million due to commercial activities for Zusduri and expanded sales operations[577] - The company initiated a strategic promotion of Zusduri in the U.S. in late June 2025, achieving open access for over 95% of covered lives[533] Cash and Financing - As of December 31, 2025, the company had $120.5 million in cash and cash equivalents and marketable securities[582] - Financing activities provided net cash of $39.9 million in 2025, a decrease of $154.7 million from $194.6 million in 2024, mainly due to reduced proceeds from share issuances[602] - The company expects to finance future cash needs through a combination of equity offerings, debt financings, and collaborations, with no assurance of securing additional financing on favorable terms[605][606] - UroGen Pharma, Inc. entered into a Securities Purchase Agreement on July 26, 2023, resulting in gross proceeds of $120.0 million from the sale of 12,579,156 ordinary shares[593] - The company completed a public offering on June 20, 2024, raising gross proceeds of $107.5 million from the sale of 5,000,000 ordinary shares[594] Tax and Accounting - The company has approximately $626.7 million in carry forward tax losses as of December 31, 2025, and does not expect to pay taxes in Israel until taxable income is generated[571] - Deferred income tax assets and liabilities are determined based on differences between financial reporting and tax bases, using currently enacted tax rates[625] - The company follows a two-step approach in recognizing uncertain tax positions, measuring benefits based on cumulative probability[626] Currency and Inflation - The company experienced a 12.5% depreciation of the U.S. dollar against the NIS during 2025, which could adversely affect dollar-denominated results of operations[629] - Inflation did not have a material effect on the company's business or financial condition during the year ended December 31, 2025[628] - The company does not currently engage in currency hedging activities but may consider using foreign currency forward and swap contracts in the future to manage currency risks[630] Share-Based Compensation - The company recognizes share-based compensation costs over the requisite service period, with performance-based awards expensed when achievement of performance criteria is probable[622] Long-Term Liabilities - The company has a long-term liability recognized under the RTW Transaction, which supports the launch of Jelmyto and development of Zusduri, with future cash payments based on net sales[624] Lease Obligations - The company has a total obligation for future minimum lease payments of $4.1 million and $5.9 million under operating and finance leases, respectively, as of December 31, 2025[611]